외래 주입 센터 시장 규모, 점유율, 동향 분석 보고서 : 치료 분야별, 소유 형태별, 연령층별, 지역별 및 부문별 예측(2026-2033년)

Ambulatory Infusion Centers Market Summary

The global ambulatory infusion centers market size was estimated at USD 40.9 billion in 2025 and is projected to grow from USD 43.7 billion in 2026 to USD 76.2 billion by 2033, growing at a CAGR of 8.3% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 36.8% in 2025. This growth is attributed to the increasing prevalence of chronic diseases, expanding use of specialty infusion therapies, and the shift toward cost-effective outpatient care. Moreover, favorable reimbursement policies, increasing investments in independent infusion centers, and growing patient preference for convenient, accessible, and personalized infusion services are further supporting market expansion.

The section below outlines the key factors driving the growth of the ambulatory infusion centers market, highlighting the rising prevalence of chronic diseases requiring long-term infusion therapies and the growing shift from hospital-based care to cost-effective outpatient settings. It also examines the increasing adoption of specialty biologics and injectable therapies, favorable reimbursement policies, expanding investments in independent infusion centers, and rising patient preference for convenient, accessible, and personalized infusion services.

Global Ambulatory Infusion Centers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on industry trends in each of the segments from 2021 to 2033. For this study, Grand View Research, Inc. has segmented the ambulatory infusion centers market report on the basis of therapy area, ownership model, age group and region:

• Therapy Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Autoimmune & Inflammatory Disorders
• Neurology
• Infectious Diseases
• Hematology
• Immunodeficiency Disorders
• Endocrine & Metabolic Disorders
• Rare Diseases
• Others
• Ownership Model Outlook (Revenue, USD Million, 2021 - 2033)
• Independent Centers
• Hospital-Owned Centers
• Physician-Owned Centers
• Specialty Pharmacy-Owned Centers
• Age Group Outlook (Revenue, USD Million, 2021 - 2033)
• Pediatric
• Adult
• Geriatric
• Regional Outlook (Revenue in USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • New Zealand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Therapy Area
  • 1.1.2. Ownership Model
  • 1.1.3. Age Group
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Therapy area outlook
  • 2.2.2. Ownership model outlook
  • 2.2.3. Age group outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Ambulatory Infusion Centers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising adoption of biologic and specialty drugs
    • 3.2.1.2. Growing shift from hospital-based infusion to cost-effective ambulatory care
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Shortage of skilled infusion nurses and healthcare professionals
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenge analysis
• 3.3. Ambulatory Infusion Centers Market Analysis Tools
  • 3.3.1. Porter's five forces analysis
  • 3.3.2. PESTLE analysis

Chapter 4. Ambulatory Infusion Centers Market: Therapy Area Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Therapy Area Market Share, 2025 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Ambulatory Infusion Centers Market by Therapy Area Outlook
  • 4.4.1. Oncology
    • 4.4.1.1. Oncology Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.4.2. Autoimmune & Inflammatory Disorders
    • 4.4.2.1. Autoimmune & Inflammatory Disorders Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.4.3. Neurology
    • 4.4.3.1. Neurology Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.4.4. Infectious Diseases
    • 4.4.4.1. Infectious Diseases Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.4.5. Hematology
    • 4.4.5.1. Hematology Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.4.6. Immunodeficiency Disorders
    • 4.4.6.1. Immunodeficiency Disorders Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.4.7. Endocrine & Metabolic Disorders
    • 4.4.7.1. Endocrine & Metabolic Disorders Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.4.8. Rare Diseases
    • 4.4.8.1. Rare Diseases Market estimates and forecast, 2021 to 2033 (USD Million)
  • 4.4.9. Others
    • 4.4.9.1. Others Market estimates and forecast, 2021 to 2033 (USD Million)

Chapter 5. Ambulatory Infusion Centers Market: Ownership Model Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Ownership Model Market Share, 2025 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Ambulatory Infusion Centers Market by Ownership Model Outlook
  • 5.4.1. Independent Centers
    • 5.4.1.1. Independent Centers Market estimates and forecast, 2021 to 2033 (USD Million)
  • 5.4.2. Hospital-Owned Centers
    • 5.4.2.1. Hospital-Owned Centers Market estimates and forecast, 2021 to 2033 (USD Million)
  • 5.4.3. Physician-Owned Centers
    • 5.4.3.1. Physician-Owned Centers Market estimates and forecast, 2021 to 2033 (USD Million)
  • 5.4.4. Specialty Pharmacy-Owned Centers
    • 5.4.4.1. Specialty Pharmacy-Owned Centers Market estimates and forecast, 2021 to 2033 (USD Million)

Chapter 6. Ambulatory Infusion Centers Market: Age Group Estimates & Trend Analysis

• 6.1. Definition and Scope
• 6.2. Age Group Market Share, 2025 & 2033
• 6.3. Segment Dashboard
• 6.4. Global Ambulatory Infusion Centers Market by Age Group Outlook
  • 6.4.1. Pediatric
    • 6.4.1.1. Pediatric Market estimates and forecast, 2021 to 2033 (USD Million)
  • 6.4.2. Adult
    • 6.4.2.1. Adult Market estimates and forecast, 2021 to 2033 (USD Million)
  • 6.4.3. Geriatric
    • 6.4.3.1. Geriatric Market estimates and forecast, 2021 to 2033 (USD Million)

Chapter 7. Ambulatory Infusion Centers Market: Regional Estimates & Trend Analysis, By Therapy Area, By Ownership Model, By Age Group

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. New Zealand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Key company market position analysis, 2025
  • 8.3.1. Option Care Health, Inc.
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Coram CVS Specialty Infusion Services
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Amerita, Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. KabaFusion
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. BioMatrix Specialty Pharmacy
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Paragon Healthcare, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Healix, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Vivo Infusion
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Pure Infusion
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. AIS Healthcare
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives